Compare HKPD & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | ADVB |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | United States |
| Employees | 27 | 31 |
| Industry | Other Pharmaceuticals | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 7.4M |
| IPO Year | N/A | N/A |
| Metric | HKPD | ADVB |
|---|---|---|
| Price | $0.44 | $5.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 81.3K | 19.3K |
| Earning Date | 08-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.19 |
| 52 Week High | $2.58 | $7.70 |
| Indicator | HKPD | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 59.95 |
| Support Level | $0.34 | $3.81 |
| Resistance Level | $0.71 | $5.59 |
| Average True Range (ATR) | 0.05 | 0.51 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 74.88 | 71.55 |
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.